GNE-7883 in Targeted Therapy Resistance

1. Introduction

The Hippo signaling pathway is an evolutionarily conserved network that regulates essential cellular processes, including organ size, cell proliferation, and apoptosis ^[2]. The terminal effectors of this pathway, the transcriptional coactivators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), are frequently hyperactivated in various human cancers ^[1]. Because YAP and TAZ lack intrinsic DNA-binding domains, they rely on interactions with the TEAD family of transcription factors (TEAD1–4) to drive oncogenic transcriptional programs ^[1][2].

Beyond driving primary tumorigenesis, YAP/TAZ activation has emerged as a prominent mechanism of intrinsic and acquired resistance to a wide array of targeted cancer therapies, including inhibitors of EGFR, ALK, BRAF, MEK, and KRAS ^[1][2]. For instance, in KRAS-driven cancers, YAP activation can compensate for KRAS inhibition, enabling continued tumor growth and survival ^[1]. Consequently, pharmacological disruption of the YAP/TAZ-TEAD interaction is a highly attractive therapeutic strategy. GNE-7883 is a recently discovered, potent, allosteric pan-TEAD small-molecule inhibitor (SMI) that addresses this need by blocking oncogenic YAP/TAZ signaling, offering a novel approach to overcoming targeted therapy resistance ^[1].

2. Pharmacological Activity

GNE-7883 exhibits potent pharmacological activity both in vitro and in vivo across multiple cancer models. In vitro, GNE-7883 potently inhibits the proliferation of YAP/TAZ-dependent cell lines, including YAP-amplified OVCAR-8 and NF2-null HCC1576, NCI-H226, and MDA-MB-231 cells, with half-maximal effective concentrations (EC50) in the submicromolar range (e.g., 115 nM for OVCAR-8 and 333 nM for NCI-H226) ^[1][2]. It also demonstrates broad efficacy across a panel of NF2-null mesothelioma cell lines ^[1].

In vivo, subcutaneous administration of GNE-7883 (250 mg/kg) achieved strong tumor growth inhibition, resulting in tumor stasis in the NCI-H226 mesothelioma xenograft model (102% tumor growth inhibition) and tumor regression in the MSTO-211H model, with a favorable tolerability profile ^[1][2].

In the context of targeted therapy resistance, GNE-7883 has shown remarkable efficacy in overcoming resistance to the KRAS G12C inhibitor sotorasib. In sotorasib-resistant NSCLC models (NCI-H358 and NCI-H23), GNE-7883 synergized strongly with sotorasib at clinically relevant concentrations, inducing substantial cell death and eliminating resistant clones ^[1]. Furthermore, in vivo studies utilizing sotorasib-resistant NCI-H358 xenografts, treatment-naive patient-derived xenograft (PDX) models (LU11786 and LU5268), and intrinsically resistant colorectal cancer (CRC) SW837 xenografts demonstrated that the combination of GNE-7883 and sotorasib led to robust antitumor responses and dramatic tumor regressions compared to single-agent treatments ^[1].

3. Molecular Mechanism of Action

GNE-7883 functions as a reversible, allosteric pan-TEAD inhibitor that binds to the conserved hydrophobic lipid (palmitate) pocket of TEAD transcription factors ^[1][2]. Unlike earlier lipid pocket binders that failed to disrupt protein-protein interactions, GNE-7883 binds between the first and second TEAD helices that form "site 2" and displaces Gln410, a residue proximal to this site. This binding allosterically alters the conformational landscape of site 2, effectively blocking the interaction between YAP/TAZ and all four human TEAD paralogs without altering the nuclear or cytosolic localization of these proteins ^[1].

At the chromatin level, GNE-7883 specifically decreases chromatin accessibility at TEAD motifs, predominantly at distal enhancer regions. This chromatin remodeling leads to the potent suppression of YAP/TAZ target genes, such as ANKRD1 and CCN1 ^[1].

In the setting of KRAS G12C inhibitor resistance, single-cell RNA sequencing (TraCe-seq) revealed that while sotorasib effectively suppresses MAPK pathway target genes, resistant cells survive through the adaptive or intrinsic reactivation of YAP/TAZ target genes. GNE-7883 overcomes this resistance by specifically suppressing the transcriptional program downstream of YAP, TAZ, and TEAD, thereby eliminating the bypass mechanism that allows cancer cells to survive KRAS inhibition ^[1].

4. Structure-Activity Relationship (SAR)

GNE-7883 was developed through the systematic optimization of a pyrazolopyrimidinone-based SMI series identified via a high-throughput time-resolved fluorescence resonance energy transfer (TR-FRET) screen ^[1]. The initial hit, Compound 1, showed activity against TEAD3 but lacked potency against TEAD4.

To improve lipid pocket binding and pan-TEAD activity, the van der Waals interactions in the lipophilic portion of the pocket were optimized. Replacing a trifluoromethyl group with a cyclohexyl group and adding a cyanopyrrolidine amide yielded Compound 2, which demonstrated significantly improved pan-TEAD protein-protein interaction disruption ^[1]. Structural analysis revealed that Compound 2 formed water-mediated interactions with Tyr333, Glu359, Ser331, and Ser377.

To further enhance pan-TEAD potency, medicinal chemistry efforts targeted Ser345 (in TEAD2), a residue sitting in an unoccupied hydrophilic region near the pocket entrance. Appending a polar pyrazine ring enabled the formation of a productive hydrogen bond with the Ser345 hydroxyl group. Balancing the overall polarity by replacing the cyanopyrrolidine with a 4-fluoromethyl azetidine led to Compound 3. Finally, the addition of a methyl group to the pyrazine heterocycle produced GNE-7883. Co-crystal structures confirmed that this methylpyrazine group interacts with Ser345 and expands the water-mediated interaction network to include Ser377 and the main-chain carbonyls of Leu345 and Val329, resulting in substantial biochemical potency gains against all TEAD paralogs, including TEAD4 ^[1].

5. Current Limitations

A primary limitation of GNE-7883 is its suboptimal pharmacokinetic profile. The compound exhibits low oral bioavailability (approximately 6% at a 25 mg/kg dose in mice), which necessitates alternative routes of administration, such as subcutaneous dosing, for in vivo rodent studies ^[1]. Additionally, the broader field of YAP/TAZ inhibitor development has historically been constrained by a reliance on xenograft cell line models, due to a lack of robust patient-derived xenograft (PDX) models driven specifically by genetic alterations in the Hippo pathway ^[1]. Although researchers successfully leveraged KRAS G12C mutant PDX models to demonstrate GNE-7883's efficacy in a resistance context, the pharmacokinetic limitations highlight the need for further formulation or structural optimization for oral delivery in humans.

6. Future Perspectives

The discovery and characterization of GNE-7883 provide strong proof-of-concept for the therapeutic viability of allosteric pan-TEAD inhibitors in oncology. By effectively shutting down the YAP/TAZ transcriptional program, GNE-7883 highlights the broad potential applications of TEAD SMIs not only as single agents in YAP/TAZ-dependent cancers (such as NF2-null mesotheliomas) but also as critical components of combination therapies ^[1][2].

Given that YAP/TAZ activation is a convergent resistance node for multiple targeted therapies (including inhibitors of EGFR, ALK, BRAF, and MEK), the synergistic effects observed with KRAS G12C inhibitors strongly support the rationale for testing pan-TEAD inhibitors in human clinical trials ^[1][2]. Future clinical execution will be essential to realize the full potential of this class of molecules in precision oncology, potentially transforming the management of treatment-refractory and adaptive drug-resistant tumors.

7. References